Skip to main
  1. Stocks
  2. Capricor Therapeutics
  3. Forecast
CAPR

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 38%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics is attractive because its lead asset, deramiocel, targets Duchenne muscular dystrophy with a differentiated cell-therapy approach and is already in Phase 3 development, giving the story tangible late-stage clinical and regulatory optionality. The FDA’s acceptance of a major BLA amendment, the extension of the PDUFA date to November 22nd, and the inclusion of 24-month HOPE-3 OLE data support a credible path to approval, while published HOPE-3 results showed a 1.2-point PUL2.0 advantage and about 54% slowing of upper-limb functional loss. Financially, the company ended 2Q:26 with $238 million in cash and reported 3Q26 net loss of $42.7 million, but that balance sheet and manageable burn help fund execution into the key regulatory window.

Bears say

Capricor Therapeutics is a highly speculative biotech with an uncertain regulatory path, as deramiocel already received a CRL in July 2025 for insufficient evidence of effectiveness and the July 2026 AdCom voted 9-3 against effectiveness for DMD cardiomyopathy. The company’s evidence base still rests on a small Phase II dataset supplemented by open-label follow-up, an external comparator, and topline Phase HOPE-3 data, which may not satisfy the FDA, while the proposed upper limb indication and November 22 review add more uncertainty. Commercially and financially, launch depends on outsourced execution, payer acceptance, and quarterly infusion logistics, and a delay could jeopardize the expected near-term non-dilutive cash infusion of >$230M and force dilution or litigation-driven disruptions.

Capricor Therapeutics (CAPR) has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 38% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction

Get the latest Capricor Therapeutics (CAPR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Capricor Therapeutics (CAPR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Buy based on their latest research and market trends.

According to 8 analysts, Capricor Therapeutics (CAPR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.19, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.19, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Capricor Therapeutics (CAPR) Analyst Forecast & Price Prediction

Get the latest Capricor Therapeutics (CAPR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Capricor Therapeutics (CAPR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CAPR stock data and trends